2023
2023 has been a year full of success for us! This amazing year was started by a great success:
50th May Hepatology Days from Czech Hepatology Society (ČLS JEP ČHS):
Best poster 1st place: PharmDr.Ivone C. Igreja Sa, PhD. “Pharmacologic blocking of the IL21 receptor improves hepatic inflammation and fibrosis in diet-induced nonalcoholic steatohepatitis”
This was followed by the most prestigious award:
Dimitris N. Chorafas Prize– Award for the best doctoral student in hard sciences from the Dimitris N. Chorafas Foundation and Israel’s Weizmann Institute of Science to PharmDr.Ivone C. Igreja Sa, PhD.
Finally, the entire team achieved outstanding success!
27th Congress of Atherosclerosis from Czech Atherosclerosis Society (CSAT):
Best Publication 1st, 2nd and 3rd place!
1st. Dohnalkova E, Bayer RL, Guo Q, Bamidele AO, Kim Lee HS, Valenzuela-Perez L, Krishnan A, Pavelko KD, Guisot NES, Bunyard P, Kim YB, Ibrahim SH, Gores GJ, Hirsova P
Rho-associated protein kinase 1 inhibition in hepatocytes attenuates nonalcoholic steatohepatitis.
Hepatol Commun 7 [IF=5.123], [AIS=1.558], (Q2).
2nd. Igreja Sa IC, Tripska K, Alaei Faradonbeh F, Hroch M, Lastuvkova H, Schreiberova J, Kacerovsky M, Pericacho M, Nachtigal P, Micuda S
Labetalol and soluble endoglin aggravate bile acid retention in mice with ethinylestradiol- induced cholestasis.
Front Pharmacol 14: 1116422. [IF= 5.988], AIS 0.992, (Q1).
3rd. Tripska K, Igreja Sa IC, Vasinova M, Vicen M, Havelek R, Eissazadeh S, Svobodova Z, Vitverova B, Theuer C, Bernabeu C, Nachtigal P.
Monoclonal anti-endoglin antibody TRC105 (carotuximab) prevents hypercholesterolemia and hyperglycemia-induced endothelial dysfunction in human aortic endothelial cells.
Front Med. 2022 Sep 7;9:845918. [IF=3.9] ; AIS=0.938 (Q2)
Best poster 1st, 2nd and 3rd place!
1st. PharmDr. Ester Dohnálková “Carvedilol impairs bile acid homeostasis in mice: implication for nonalcoholic steatohepatitis”
2nd. PharmDr. Katarína Tripská, PhD “Endoglin blockage is crucial in inflammation-induced endothelial dysfunction in vitro”
3rd. Mgr. Martina Vašinová “Blockage of endoglin prevents endothelial dysfunction development in type II diabetic coronary artery endothelial cells"
2022
26th Congress of Atherosclerosis from Czech Atherosclerosis Society (CSAT):
Best poster 1st and 2nd place:
1st. PharmDr. Ivone Cristina Igreja Sá, PhD “Pharmacologic blocking of IL21 receptor ameliorates diet-induced nonalcoholic steatohepatitis”
2nd. PharmDr. Ester Dohnálková “Novel ROCK inhibitor attenuates insulin resistance and steatohepatitis in a murine model of obesity-induced nonalcoholic fatty liver disease (NASH)”
Travel grant for the 90th EAS Congress in Milan from the Czech Society for Atherosclerosis (CSAT) to Mgr. Katarína Tripská.
2021
25th Congress of Atherosclerosis from Czech Atherosclerosis Society (CSAT):
Best Publication:
3rd. Place Igreja Sa IC, Tripska K., Hroch M., Hyspler R., Ticha A., Lastuvkova H., Schreiberova J., Dolezelova E., Eissazadeh S ., Vitverova B., Najmanova I., Vasinova M., Pericacho M., Micuda S., and Nachtigal P.
Soluble Endoglin as a Potential Biomarker of Nonalcoholic Steatohepatitis (NASH) Development, Participating in Aggravation of NASH-Related Changes in Mouse Liver
Int J Mol Sci 2020;21(23). [IF = 4.556], (Q1), [AIS = 0.947], (Q2)
Best poster:
1st. Mgr. Katarína Tripská “ENDOGLIN BLOCKAGE IS ESSENTIAL IN HYPERCHOLESTEROLEMIA AND HYPERGLYCEMIA INDUCED ENDOTHELIAL DYSFUNCTION IN HAECS”
2020
24th Congress of Atherosclerosis from Czech Atherosclerosis Society (CSAT):
Best poster:
1st. Mgr. Ivone Cristina Igreja Sá “Soluble endoglin aggravates NASH progression in mouse liver”
2nd. Mgr. Katarína Tripská “Carotuximab affects 7-ketocholesterol induced endothelial dysfunction in HAEC via endoglin? – a pilot study”
l
Best Poster (2nd Place) – 23rd Congress of Atherosclerosis from Czech Atherosclerosis Society (CSAT) 2019
Soluble endoglin, cholesterol and bile acids metabolism in NASH mouse model
Igreja Sa IC, Prasnicka A, Lastuvkova H, Hroch M, Hyspler R, Dolezelova E, Micuda S, Nachtigal P
The first price award for the best original paper (article) published in 2018 from Czech Atherosclerosis Society:
Vitverova B, Blazickova K, Najmanova I, Vicen M, Hyspler R, Dolezelova E, Nemeckova I, Tebbens JD, Bernabeu C, Pericacho M, Nachtigal P. Soluble endoglin and hypercholesterolemia aggravate endothelial and vessel wall dysfunction in mouse aorta. Atherosclerosis. 2018;271:15-25 IF= 4,467.
The first price award for the best poster in Congress of Atherosclerosis from Czech Atherosclerosis Society 2018:
Endoglin role in oxysterol induced endothelial dysfunction in human aortic endothelial cells.
Matej Vicen, Radim Havelek, Miloslav Machacek, Katarína Tripská, Barbora Vitverova, Petr Nachtigal
The first price award for the best poster in Congress of Atherosclerosis from Czech Atherosclerosis Society 2017:
Eva Dolezelova, Alena Prasnicka, Jolana Cermanova, Milos Hroch, Radek Hyspler, Alena Ticha, Jose M. Lopez-Novoa, Stanislav Micuda., Petr Nachtigal. Human soluble endoglin induces choleretic and hypocholesterolemic effect in transgenic mice.
The first price award for the best poster in Congress of Atherosclerosis from Czech Atherosclerosis Society 2016:
B. Vitverova, K. Jezkova, J. Rathouska, I. Nemeckova, S. Chlopicki, P. Nachtigal. "Changes of membrane and soluble endoglin levels as a possible biomarker of endothelial dysfunction."
The first price award for the best original paper (article) published in 2014 from Czech Atherosclerosis Society:
Rathouska J, Jezkova K, Nemeckova I, Zemankova L, Varejckova M, Nachtigal P. Endoglin is not expressed with cell adhesion molecules in aorta during atherogenesis in apoe-deficient mice. Histol Histopathol. 2015;30:233-244
Poster Award New Frontiers in Basic Cardiovascular Research: I. Nemeckova, O. Lencova, E. Jirkovsky, M. Adamcova, P. Nachtigal, M. Sterba "Cardiotoxicity of chronic sunitinib treatment in normotensive and spontaneously hypertensive rats."
The first price award for the best original paper (article) published in 2011 from Czech Atherosclerosis Society:
Stráský Z. et al.: Cholesterol effects on endoglin and its downstream pathways in ApoE/LDLR double knockout mice Circ J. 2011;75 (7):1747-55.
The first price award for the best original paper (article) published in 2009 from Czech Atherosclerosis Society:
Nachtigal et al: Atorvastatin increases endoglin, SMAD2, phosphorylated SMAD2/3 and eNOS expression in ApoE/LDLR double knockout mice J Atheroscler Thromb 16: 265-274; 2009.